Onconova Therapeutics Inc. Appoints Dr. Thomas J. McKearn as President, Research and Development

Onconova Therapeutics Inc. Appoints Dr. Thomas J. McKearn as President, Research and Development

10/9/2012 10:35:24 AM

NEWTOWN, Pa. & PENNINGTON, N.J.--(BUSINESS WIRE)--Onconova Therapeutics, Inc. today announced the appointment of Thomas J. McKearn, M.D., Ph.D. as President, Research and Development. Dr. McKearn is a veteran drug development executive who most recently served as Vice President, Strategic Clinical Affairs at Agennix, Inc. "Thomas brings substantial leadership experience in all key aspects of drug development to Onconova, including research, clinical development, business operations, and corporate development," said Ramesh Kumar, Chief Executive Officer of Onconova. "I am very pleased to welcome him to our executive team and look forward to his contributions as the Phase III trial of rigosertib in Myelodysplastic Syndromes progresses toward pivotal data in 2013."

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.